ep top consensu ep beat
better revenu off-set lower profit factor
line drove ep beat importantli unveil ep
guidanc vs consensu owe part continu
pharmedium challeng consequ lower ep
estim reflect lighter core pharma distribut
oper assumpt tp move calendar
ebitda estim lower view
revenu ahead profit sink revenu growth vs
estimate driven stronger core pharma distribut experi
well better expect perform distribut includ
specialti acquisit rose vs estimate despit
on-going pharmedium challeng rose healthi well
plan repres profit key compon posit
thesi gross margin bp bp plan oper
expens bp bp higher plan ebit margin
deterior bp bp view key focu area
oper profit distribut well plan
gener million cash fund million share repurchas
share may retreat share subsid lighter
expect guidanc neg impact on-going pharmedium
woe memphi facil remain shutter commun
fda guidanc call lsd msd dist oper profit
growth target impli solid msd core distribut unit
exclud pharmedium encourag dynam outlin call
rhetor washington continu weigh suppli chain name
view well posit amongst distributor given focu non-
tradit busi pharmedium challeng hope wane
time see revenu profit driver wba matur pharmaci
relationship onboard esrx relationship contribut
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
global pharmaceut sourc
price rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
bottom rang
competit less price
buysid in-lin expect
sell-sid see
market environ competit
stabl
sell side still see
competit rel stabl
sell side continu see
slightli msd full-year
mid-single-digit high-singl digit
continu evalu much
valu expectclearli
month juli run rate
less would
follow pattern
environ competit
stabl
compani mention price
